Literature DB >> 7704464

Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature.

J A Avina-Zubieta1, E S Johnson, M E Suarez-Almazor, A S Russell.   

Abstract

A retrospective review of 4405 patients' charts identified 214 patients who initiated antimalarial therapy between January 1987 and April 1993 for different rheumatic disorders (mean duration of therapy of 17 months). From these, three patients with myopathy were found for a total of 303 patient-years of therapy, for an incidence of 1 in 100 patient-years (95%, confidence interval 0.2-3). All three patients had rheumatoid arthritis and had received chloroquine for between 12 and 18 months with a maximum dose of 250 mg/daily. All had a muscle biopsy, but only one showed the classical rimmed vacuoles. All patients improved within 2 months after the drug was stopped. A review of the literature was carried out with special reference to the significance of clinical myopathy with a negative biopsy. We found that positive biopsies are usual only if the duration of symptoms have been allowed to persist for more than 6 months.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704464     DOI: 10.1093/rheumatology/34.2.166

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

2.  [Occurrence of chloroquine-induced myopathy after low-dose treatment of rheumatoid arthritis for seven years].

Authors:  A Haberl; P Fischer; D Pongratz; J P Sieb
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

3.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

4.  The role of neutrophil extracellular traps and TLR signaling in skeletal muscle ischemia reperfusion injury.

Authors:  Nicole J Edwards; Charles Hwang; Simone Marini; Chase A Pagani; Philip J Spreadborough; Cassie J Rowe; Pauline Yu; Annie Mei; Noelle Visser; Shuli Li; Geoffrey E Hespe; Amanda K Huber; Amy L Strong; Miriam A Shelef; Jason S Knight; Thomas A Davis; Benjamin Levi
Journal:  FASEB J       Date:  2020-10-22       Impact factor: 5.191

5.  Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.

Authors:  E Casado; J Gratacós; C Tolosa; J M Martínez; I Ojanguren; A Ariza; J Real; A Sanjuán; M Larrosa
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

6.  Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.

Authors:  Jutta G Richter; Arnd Becker; Benedikt Ostendorf; Christof Specker; G Stoll; E Neuen-Jacob; Matthias Schneider
Journal:  Rheumatol Int       Date:  2003-05-09       Impact factor: 2.631

7.  Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.

Authors:  Thomas Khoo; Sophia Otto; Caroline Smith; Barbara Koszyca; Sue Lester; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2016-09-14       Impact factor: 2.980

8.  Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.

Authors:  A Dugué; H Bagheri; M Lapeyre-Mestre; J F Tournamille; L Sailler; G Dedieu; R Salvayre; J P Thouvenot; P Massip; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

Review 9.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Drug-induced musculoskeletal disorders.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.